The European Alliance for Personalised Medicine was launched in March 2012, with the aim of improving patient care by accelerating the development, delivery and uptake of personalised medicine and earlier diagnostics, through consensus.
EAPM began as a response to the need for a wider understanding of priorities in personalised medicine and a more integrated approach among distinct lay and professional stakeholders. It continues to fulfil that role, not least through regular major events and non-stop interaction via the media.
The Alliance’s stakeholders focus not just on the delivery of the right treatment for the right patient at the right time, but also on the right preventative measures to ensure reliable and sustainable healthcare.
The mix of EAPM members and its broader stakeholder outreach provides extensive scientific, clinical, caring and training expertise in personalised medicine and diagnostics, across patient groups, academia, health professionals and industry.
Relevant departments of the European Commission have observer status, as does the EMA, and our engagement with Members of the European Parliament and Member State health ministries in key policy areas is a crucial part of our ongoing work.